Pierre d’Epenoux, ImCheck CEO
September 15, 2020 07:18 AM EDT
Financing

Im­Check adds $7.1M to Se­ries B, boost­ing de­vel­op­ment of gam­ma delta T cell pro­grams

Max Gelman

Senior Editor

Nine months af­ter first an­nounc­ing a Se­ries B, French biotech Im­Check re­turned to the ven­ture cap­i­tal well seek­ing a bit more cash.

The com­pa­ny found …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times